<DOC>
	<DOCNO>NCT01406574</DOCNO>
	<brief_summary>The purpose study : Phase1 : To evaluate safety determine recommend dose ( RD ) Phase2 : To evaluate efficacy</brief_summary>
	<brief_title>Phase I/II Study OPB-31121 Patients With Progressive Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients histopathologically clinically confirm diagnosis hepatocellular carcinoma Patients ChildPugh classification A B Patients unresponsive standard therapy standard therapy intolerable , appropriate therapy Patients able take oral medication Patients age 20 79 year ( inclusive ) time informed consent Patients ECOG performance status score 02 Patients eligible organ function . Patients primary malignant tumor Patients history liver transplant Patients brain metastasis Patients complication uncontrolled Patients psychiatric disorder might cause difficulty obtain informed consent conduct trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>